DK1171137T3 - Anvendelse af triacetyluridin til behandling af mitochondriale lidelser - Google Patents

Anvendelse af triacetyluridin til behandling af mitochondriale lidelser

Info

Publication number
DK1171137T3
DK1171137T3 DK00910321T DK00910321T DK1171137T3 DK 1171137 T3 DK1171137 T3 DK 1171137T3 DK 00910321 T DK00910321 T DK 00910321T DK 00910321 T DK00910321 T DK 00910321T DK 1171137 T3 DK1171137 T3 DK 1171137T3
Authority
DK
Denmark
Prior art keywords
mitochondrial disorders
treatment
triacetyluridine
methods
mitochondrial
Prior art date
Application number
DK00910321T
Other languages
Danish (da)
English (en)
Inventor
Robert K Naviaux
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of DK1171137T3 publication Critical patent/DK1171137T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
DK00910321T 1999-02-23 2000-02-23 Anvendelse af triacetyluridin til behandling af mitochondriale lidelser DK1171137T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12158899P 1999-02-23 1999-02-23
PCT/US2000/004663 WO2000050043A1 (en) 1999-02-23 2000-02-23 Methods of treatment of mitochondrial disorders

Publications (1)

Publication Number Publication Date
DK1171137T3 true DK1171137T3 (da) 2008-03-31

Family

ID=22397641

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00910321T DK1171137T3 (da) 1999-02-23 2000-02-23 Anvendelse af triacetyluridin til behandling af mitochondriale lidelser

Country Status (20)

Country Link
US (2) US7638501B1 (enExample)
EP (2) EP1171137B1 (enExample)
JP (1) JP4776780B2 (enExample)
KR (2) KR100879559B1 (enExample)
CN (2) CN1191835C (enExample)
AT (1) ATE381935T1 (enExample)
AU (1) AU776437B2 (enExample)
BR (1) BR0008447A (enExample)
CA (1) CA2362925C (enExample)
DE (1) DE60037578T2 (enExample)
DK (1) DK1171137T3 (enExample)
ES (1) ES2298130T3 (enExample)
HU (1) HU230191B1 (enExample)
IL (3) IL144964A0 (enExample)
MX (1) MXPA01008549A (enExample)
NZ (1) NZ513926A (enExample)
PT (1) PT1171137E (enExample)
RU (2) RU2268732C2 (enExample)
WO (1) WO2000050043A1 (enExample)
ZA (1) ZA200107727B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306909B1 (en) 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
US8143234B2 (en) * 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US8518882B2 (en) * 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
US6989376B2 (en) * 1998-07-31 2006-01-24 Massachusetts Institute Of Technology Methods for increasing blood cytidine and/or uridine levels and treating cytidine-dependent human diseases
US8314064B2 (en) * 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
KR100879559B1 (ko) 1999-02-23 2009-01-22 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 미토콘드리아 장애의 치료 또는 예방용 제약조성물
US6727231B1 (en) * 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
DE10110355A1 (de) 2001-03-03 2002-09-12 Ulrich Walker Bekämpfung von Nebenwirkungen
EP1385831A2 (en) * 2001-04-11 2004-02-04 Queen's University At Kingston Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents
JP4105626B2 (ja) * 2001-05-29 2008-06-25 ザ ユニバーシティ オブ ブリティッシュ コロンビア ミトコンドリアｄｎａアッセイの薬理学的応用
JP2004182705A (ja) * 2002-10-11 2004-07-02 Yasutoshi Koga ミトコンドリア機能異常に起因する疾患における臨床症状発現の予防・治療用組成物
AU2004209522A1 (en) * 2003-01-17 2004-08-19 Gilead Palo Alto, Inc. Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
WO2006130775A2 (en) 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
PT1933821T (pt) * 2005-09-15 2020-10-15 Ptc Therapeutics Inc Variantes de cauda de terapêuticos redox-ativos para tratamento de doenças mitocondriais e outras condições e modulação de biomarcadores energéticos
JP5374162B2 (ja) 2006-02-22 2013-12-25 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
US8748405B2 (en) 2007-01-26 2014-06-10 City Of Hope Methods and compositions for the treatment of cancer or other diseases
EP2217075A4 (en) 2007-11-02 2012-01-25 Massachusetts Inst Technology URIDINE FOOD ADDITIONAL AGREEMENT PROCESS AND USE THEREOF
CN101612110B (zh) * 2008-06-23 2012-07-25 欣凯医药化工中间体（上海）有限公司 三乙酰尿苷缓释制剂及其制备方法
EP3827815B1 (en) 2008-09-10 2023-09-06 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
RU2400221C2 (ru) * 2008-11-11 2010-09-27 ФГУ "Московский НИИ педиатрии и детской хирургии Росмедтехнологий" Способ лечения врожденных структурных миопатий и врожденных мышечных дистрофий путем коррекции вторичных митохондриальных изменений
ES2640485T3 (es) * 2011-08-12 2017-11-03 Universitätsklinikum Freiburg Uridina y análogos de uridina para el uso en el tratamiento de la enfermedad pulmonar obstructiva crónica
WO2015106255A1 (en) 2014-01-13 2015-07-16 City Of Hope Multivalent oligonucleotide assemblies
DK3182980T3 (da) * 2014-08-19 2021-01-11 Wellstat Therapeutics Corp Behandling af glykosyleringsmangelsygdomme
FR3027804A1 (fr) * 2014-10-31 2016-05-06 Centre Nat Rech Scient Utilisation d'un inhibiteur de transcriptase inverse dans la prevention et le traitement des maladies degeneratives
BR112017022578A2 (pt) 2015-05-29 2018-07-17 The Board Of Trustees Of The Leland Stanford Junior University agentes nucleosídicos para a redução da atividade deletéria de genes que contém repetições estendidas de nucleotídeos
PL3302499T3 (pl) * 2015-06-05 2023-07-24 Fundació Hospital Universitari Vall D'hebron - Institut De Recerca Leczenie chorób mitochondrialnych
US10471087B2 (en) * 2015-06-17 2019-11-12 The Trustees Of Columbia University In The City Of New York Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes
US10703701B2 (en) 2015-12-17 2020-07-07 Ptc Therapeutics, Inc. Fluoroalkyl, fluoroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
KR101981843B1 (ko) 2016-09-13 2019-05-23 울산대학교 산학협력단 일산화탄소 또는 일산화탄소 공급체를 유효성분으로 함유하는 미토콘드리아 기능 개선용 조성물
AU2019242628A1 (en) 2018-03-26 2020-09-24 Clear Creek Bio, Inc. Compositions and methods for inhibiting dihydroorotate dehydrogenase
CN114340641B (zh) * 2019-09-05 2025-04-04 米托瑞因博治疗股份有限公司 治疗线粒体dna缺失障碍
US12076315B2 (en) 2020-03-20 2024-09-03 Clear Creek Bio, Inc. Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
KR102290596B1 (ko) * 2020-09-10 2021-08-19 주식회사 파이안바이오테크놀로지 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도
KR20230067613A (ko) * 2020-09-14 2023-05-16 웰스태트 테러퓨틱스 코포레이션 5' 위치에서 아세토아세틸로 치환된 2',3'-디아세틸우리딘
EP3970713A1 (en) 2020-09-16 2022-03-23 GV Squared S.r.l. Pharmaceutical composition comprising uridine and pyruvate for regulating the profileration, activity and survival of immune cells
CN113116900B (zh) * 2021-04-14 2022-07-08 兰州大学 一类核苷类似物在制备预防和/或治疗脑血管疾病药物中的应用
BE1030026B1 (fr) * 2022-06-14 2023-07-07 Dendrogenix Composés dérivés de stérols et composition pharmaceutique les comprenant pour leur utilisation dans la prévention, l’amélioration et/ou le traitement d’une pathologie liée à un déficit mitochondrial

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas Blanchard Machine for mortising solid wooden shells of ships' tackle-blocks
JPS5356690A (en) * 1976-09-30 1978-05-23 Rikagaku Kenkyusho Purin compund sugar derivatives and their preparation
US7173017B1 (en) 1987-10-28 2007-02-06 Wellstat Therapeutics Corporation Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
JP2894610B2 (ja) * 1987-10-28 1999-05-24 プロ−ニューロン，インコーポレーテッド アシル化ウリジンおよびシチジンならびにその使用
US6348451B1 (en) 1987-10-28 2002-02-19 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US7307166B1 (en) 1987-10-28 2007-12-11 Wellstat Therapeutics Corporation Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis
US6743782B1 (en) 1987-10-28 2004-06-01 Wellstat Therapeutics Corporation Acyl deoxyribonucleoside derivatives and uses thereof
US5736531A (en) 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US6329350B1 (en) 1987-10-28 2001-12-11 Pro-Neuron, Inc. Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
ATE243039T1 (de) 1987-10-28 2003-07-15 Wellstat Therapeutics Corp Acyldeoxyribonukleosid-derivate und verwendungen davon
IT1219667B (it) 1988-06-21 1990-05-24 Polifarma Spa Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
DE3843241A1 (de) * 1988-12-22 1990-06-28 Skrezek Christian Nephroprotektive infusionsloesung
IT1241984B (it) 1990-06-13 1994-02-02 Polifarma Spa Impiego di uridina nel trattamento farmacologico delle complicazioni periferiche del diabete
ES2224098T3 (es) * 1992-05-28 2005-03-01 Centre For Molecular Biology And Medicine, Derivados de quinona para aumentar la bioenergia celular.
US5567689A (en) 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5852000A (en) 1993-08-25 1998-12-22 Otsuka Pharmaceutical Factory, Inc. Cardiac rehabilitation agent
AU705230B2 (en) * 1994-03-30 1999-05-20 Mitokor Diagnosis, therapy and cellular and animal models for diseases associated with mitochondrial defects
JP3808121B2 (ja) * 1995-01-09 2006-08-09 日本メジフィジックス株式会社 低酸素症またはミトコンドリア機能障害診断剤
US5962459A (en) 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
JPH10273469A (ja) * 1997-02-03 1998-10-13 Takeda Chem Ind Ltd ２環性キノン誘導体、製造法および剤
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
KR100879559B1 (ko) 1999-02-23 2009-01-22 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 미토콘드리아 장애의 치료 또는 예방용 제약조성물

Also Published As

Publication number Publication date
CN1626107A (zh) 2005-06-15
EP1808177A3 (en) 2010-07-28
AU2004235661A1 (en) 2005-01-27
RU2005121711A (ru) 2007-01-20
DE60037578T2 (de) 2009-01-08
BR0008447A (pt) 2002-01-15
CA2362925C (en) 2011-04-12
US8748408B2 (en) 2014-06-10
ES2298130T3 (es) 2008-05-16
IL180528A0 (en) 2007-06-03
PT1171137E (pt) 2008-03-17
CN1191835C (zh) 2005-03-09
EP1171137A4 (en) 2004-04-07
CN1341024A (zh) 2002-03-20
KR100879559B1 (ko) 2009-01-22
EP1808177B1 (en) 2018-08-08
US20100098678A1 (en) 2010-04-22
JP2002537340A (ja) 2002-11-05
EP1171137A1 (en) 2002-01-16
RU2001125913A (ru) 2005-02-20
EP1808177A2 (en) 2007-07-18
ZA200107727B (en) 2007-10-31
CA2362925A1 (en) 2000-08-31
HUP0400914A3 (en) 2007-05-29
DE60037578D1 (de) 2008-02-07
EP1171137B1 (en) 2007-12-26
IL144964A (en) 2013-11-28
KR20020031331A (ko) 2002-05-01
IL144964A0 (en) 2002-06-30
RU2268732C2 (ru) 2006-01-27
ATE381935T1 (de) 2008-01-15
WO2000050043A1 (en) 2000-08-31
US7638501B1 (en) 2009-12-29
JP4776780B2 (ja) 2011-09-21
AU3243400A (en) 2000-09-14
IL180528A (en) 2013-11-28
KR100758712B1 (ko) 2007-09-14
MXPA01008549A (es) 2003-06-06
CN100379426C (zh) 2008-04-09
KR20070085864A (ko) 2007-08-27
HU230191B1 (hu) 2015-09-28
AU776437B2 (en) 2004-09-09
RU2394580C2 (ru) 2010-07-20
HUP0400914A2 (hu) 2004-08-30
NZ513926A (en) 2001-09-28

Similar Documents

Publication Publication Date Title
DK1171137T3 (da) Anvendelse af triacetyluridin til behandling af mitochondriale lidelser
BRPI0411825B8 (pt) inibidores de p38 quinase a base de heterociclo de 5 elementos, seus processos de preparação e seus usos, bem como composição farmacêutica
AU2003272285A8 (en) Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
CR6577A (es) Inhibidores triciclicos de poli(adp-ribosa) polimerasas
ATE225341T1 (de) In 6-position durch thio substituierte paclitaxele
NO20035524D0 (no) 4'-substituerte nukleosider
DK1196172T3 (da) (S,S)-reboxetin til behandling af kronisk smerte
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
BRPI0415699A (pt) uso de oligossacarìdeo ácido e de oligossacarìdeo neutro, e, composições alimentìcia e lìquida
ATE433973T1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
NO20021379L (no) Benzodiazepin-derivater, fremstilling og anvendelse derav
ES2318119T3 (es) Procedimiento y composiciones para alterar el perfil del efecto edulcorante de la sucralosa.
BRPI0512547A (pt) pirimidinas
CY1111762T1 (el) Διενυδρη παμοϊκη ολανζαπiνη
ATE439363T1 (de) Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides
DK1220852T3 (da) Substituerede diazepaner
TR200102008T2 (tr) Serebral işemi profilaksı ve tedavisi için piridin türevlerinin kullanımı.
DE60135358D1 (de) Uridin-therapie für patienten mit erhöhten purin-werten
DK0580753T3 (da) Pyrimidinderivater til forøgelse af antitumoraktivitet
BR0101245B1 (pt) barra de direção ajustável com travamento longitudinal.
NO20060420L (no) 2-aminobenzoylderivater
NO20025303L (no) Anvendelse av substituerte akryloyl-distamycin-derivater i behandlingen avtumorer assosiert med höye nivåer av glutation
BRPI0511125A (pt) usos de ácido 5,6,7-triidroxieptanóico seus e análogos
NO20065791L (no) Asyklovir-formuleringer
ATE398134T1 (de) Neue analoga von nitrobenzylthioinosin